Abbvie, attractive valuation but some side notes.
Abbvie with sector report. The company has been compared with 16 other pharmaceutial and biotechnoly companies. Helpfull with easy and appropriate fund allocation guidelines within the sector. Abbvie its high amount of debt catches the eye and is somewhat special.
AbbVie is a research-based biopharmaceutical company. The company's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. The company also has medicines in clinical development across immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.
Analist is and analysis by drs. E. (Erik) D. Molenaar RBA, RBA/CFA certified investment analist and EFFAS certified financial analist. Delivering to the point investment analysis. Apart from an absolute advice, a clear sector advice and overview, and/or a relative advice within the sector, is always included in the reports which makes the reports extremely usefull and helpfull for fund allocation within a sector.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.